BioCardia (NASDAQ:BCDA) Shares Down 4.1% – Here’s Why

by · The Markets Daily

Shares of BioCardia, Inc. (NASDAQ:BCDA – Get Free Report) fell 4.1% on Tuesday . The company traded as low as $1.1625 and last traded at $1.18. 97,856 shares were traded during trading, an increase of 10% from the average session volume of 88,955 shares. The stock had previously closed at $1.23.

Analysts Set New Price Targets

Several equities analysts recently commented on the stock. HC Wainwright reiterated a “buy” rating and set a $25.00 price target on shares of BioCardia in a report on Monday, September 22nd. Wall Street Zen upgraded BioCardia to a “sell” rating in a report on Saturday, November 1st. Weiss Ratings restated a “sell (e+)” rating on shares of BioCardia in a report on Wednesday, October 8th. Finally, Zacks Research upgraded shares of BioCardia to a “hold” rating in a research note on Tuesday, September 23rd. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $25.00.

View Our Latest Research Report on BioCardia

BioCardia Price Performance

The stock’s 50-day moving average is $1.34 and its 200 day moving average is $1.70. The company has a market cap of $12.52 million, a PE ratio of -0.80 and a beta of 0.67.

BioCardia (NASDAQ:BCDA – Get Free Report) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($0.24) EPS for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.01. On average, analysts expect that BioCardia, Inc. will post -3.52 EPS for the current year.

Institutional Investors Weigh In On BioCardia

An institutional investor recently bought a new position in BioCardia stock. Cetera Investment Advisers purchased a new stake in BioCardia, Inc. (NASDAQ:BCDA – Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 20,275 shares of the company’s stock, valued at approximately $40,000. Cetera Investment Advisers owned 0.37% of BioCardia at the end of the most recent quarter. Hedge funds and other institutional investors own 20.57% of the company’s stock.

BioCardia Company Profile

(Get Free Report)

BioCardia, Inc is a clinical-stage biotechnology company dedicated to developing novel cell-based therapies for patients with cardiovascular disease. The company’s core focus lies in advancing regenerative medicine approaches that address both chronic heart failure and acute myocardial infarction. BioCardia leverages proprietary delivery technologies to optimize the targeted administration of therapeutic cells directly into the heart muscle.

The company’s flagship products include the Helix Transendocardial Delivery System and the CardiAMP Cell Therapy System.

Further Reading